Thomson Horstmann Bryant Inc Lowers stake in Sagent Pharmaceuticals Inc (SGNT)

Sagent Pharmaceuticals Inc (SGNT) : Thomson Horstmann Bryant Inc reduced its stake in Sagent Pharmaceuticals Inc by 1.48% during the most recent quarter end. The investment management company now holds a total of 632,499 shares of Sagent Pharmaceuticals Inc which is valued at $13,718,903 after selling 9,491 shares in Sagent Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.Sagent Pharmaceuticals Inc makes up approximately 1.70% of Thomson Horstmann Bryant Inc’s portfolio.

Other Hedge Funds, Including , Hartford Investment Management Co added SGNT to its portfolio by purchasing 13,300 company shares during the most recent quarter which is valued at $288,477. Sagent Pharmaceuticals Inc makes up approx 0.01% of Hartford Investment Management Co’s portfolio.Simplex Trading reduced its stake in SGNT by selling 922 shares or 61.02% in the most recent quarter. The Hedge Fund company now holds 589 shares of SGNT which is valued at $12,775.Cutler Group Lp reduced its stake in SGNT by selling 200 shares or 15.38% in the most recent quarter. The Hedge Fund company now holds 1,100 shares of SGNT which is valued at $23,936.Creative Planning boosted its stake in SGNT in the latest quarter, The investment management firm added 846 additional shares and now holds a total of 948 shares of Sagent Pharmaceuticals Inc which is valued at $20,628.Bnp Paribas Arbitrage Sa boosted its stake in SGNT in the latest quarter, The investment management firm added 3,896 additional shares and now holds a total of 7,449 shares of Sagent Pharmaceuticals Inc which is valued at $115,460.

Sagent Pharmaceuticals Inc closed down -0.04 points or -0.18% at $21.69 with 5,41,511 shares getting traded on Wednesday. Post opening the session at $21.73, the shares hit an intraday low of $21.67 and an intraday high of $21.75 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Sagent Pharmaceuticals Inc reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.00. The company had revenue of $67.80 million for the quarter, compared to analysts expectations of $74.22 million. The company’s revenue was down -17.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.04 EPS.

Many Wall Street Analysts have commented on Sagent Pharmaceuticals Inc. Sagent Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 11, 2016. Sagent Pharmaceuticals Inc was Downgraded by Raymond James to ” Mkt Perform” on Jul 11, 2016. Shares were Reiterated by RBC Capital Mkts on May 4, 2016 to “Outperform” and Lowered the Price Target to $ 20 from a previous price target of $28 .

Sagent Pharmaceuticals Inc. (Sagent) formerly Sagent Holding Co. is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective oncolytic and critical care indications in a variety of presentations including single- and multi-dose vials pre-filled ready-to-use syringes medical devices and premix bags. As of October 31 2010 Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides) which is an Indian manufacturer of finished pharmaceutical products.

Leave a Reply

Sagent Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sagent Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.